# BLIS Technologies

the strain-science pioneer — Streptococcus salivarius K12 and M18, with four new peer-reviewed studies landed in the first half of 2026.


Source: https://en.bioecon.ru/companies/blis-technologies/
Updated: 2026-07-28

- Country: NZ

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | 6 prior funding rounds | https://media.businessdesk.co.nz/file/aGpn2i1H.pdf, https://media.businessdesk.co.nz/file/kd4wS4BP.pdf, https://new.nzx.com/announcements/473000, https://www.nzx.com/announcements/473000 |
| Capacity | Probi has full-scale production capacity of both bulk powder and product applications of BLIS K12 and BLIS M18 strains in Redmond, Washington | https://www.probi.com/press-releases/2023/05/probi-takes-over-all-distribution-of-blis-k12-and-blis-m18-in-north-america/ |
| Certification | B Corp certification and MyGreen Lab certification maintained | https://blis.co.nz/press/most-studied-oral-probiotic-strains-for-dental-health-a-guide-to-the-clinical-evidence/, https://media.businessdesk.co.nz/file/aGpn2i1H.pdf |
| Regulatory approval | US GRAS status held by BLIS K12 and BLIS M18 | https://blis.co.nz/press/most-studied-oral-probiotic-strains-for-dental-health-a-guide-to-the-clinical-evidence/ |
| Production site | Dunedin, New Zealand (manufacturing site) | https://aeroleads.com/c/blis-technologies-limited, https://blis.co.nz/facilities/ |
| Headcount | approximately 32 employees | https://aeroleads.com/c/blis-technologies-limited |
| Revenue | $14.7 million for the year ended 31 March 2026 | https://media.businessdesk.co.nz/file/aGpn2i1H.pdf, https://media.businessdesk.co.nz/file/kd4wS4BP.pdf, https://new.nzx.com/announcements/473000, https://www.nzx.com/announcements/473000 |

Independent sources: aeroleads.com, media.businessdesk.co.nz, new.nzx.com, nzx.com, probi.com

## Technologies

- [Probiotic oral care](https://en.bioecon.ru/technology/probiotic-oral-care/)